Your browser doesn't support javascript.
loading
Pharmacokinetic boosting of olaparib: A randomised, cross-over study (PROACTIVE-study).
Overbeek, Joanneke K; Guchelaar, Niels A D; Mohmaed Ali, Ma Ida; Ottevanger, Petronella B; Bloemendal, Haiko J; Koolen, Stijn L W; Mathijssen, Ron H J; Boere, Ingrid A; Hamberg, Paul; Huitema, Alwin D R; Sonke, Gabe S; Opdam, Frans L; Ter Heine, Rob; van Erp, Nielka P.
Afiliação
  • Overbeek JK; Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, Gelderland, the Netherlands. Electronic address: Joanneke.Overbeek@radboudumc.nl.
  • Guchelaar NAD; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, South Holland, the Netherlands.
  • Mohmaed Ali MI; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, North Holland, the Netherlands.
  • Ottevanger PB; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, Gelderland, the Netherlands.
  • Bloemendal HJ; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, Gelderland, the Netherlands.
  • Koolen SLW; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, South Holland, the Netherlands; Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, South Holland, the Netherlands.
  • Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, South Holland, the Netherlands.
  • Boere IA; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, South Holland, the Netherlands.
  • Hamberg P; Department of Internal Medicine, Franciscus Gasthuis and Vlietland, Rotterdam, South Holland, the Netherlands.
  • Huitema ADR; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, North Holland, the Netherlands; Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrecht, Utrecht, the Netherlands; Department of Clinical Pharmacy, University Medical Center Utrecht, Utre
  • Sonke GS; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, North Holland, the Netherlands.
  • Opdam FL; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, North Holland, the Netherlands.
  • Ter Heine R; Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, Gelderland, the Netherlands.
  • van Erp NP; Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, Gelderland, the Netherlands.
Eur J Cancer ; 194: 113346, 2023 11.
Article em En | MEDLINE | ID: mdl-37806255
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperazinas / Citocromo P-450 CYP3A Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperazinas / Citocromo P-450 CYP3A Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article